Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Assets (2023 - 2025)

Monte Rosa Therapeutics' Assets history spans 3 years, with the latest figure at $448.7 million for Q4 2025.

  • For Q4 2025, Assets rose 2.26% year-over-year to $448.7 million; the TTM value through Dec 2025 reached $448.7 million, up 2.26%, while the annual FY2025 figure was $448.7 million, 2.26% up from the prior year.
  • Assets reached $448.7 million in Q4 2025 per GLUE's latest filing, down from $459.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $459.8 million in Q3 2025 to a low of $252.1 million in Q3 2023.
  • Average Assets over 3 years is $347.5 million, with a median of $329.6 million recorded in 2024.
  • Peak YoY movement for Assets: fell 13.68% in 2024, then surged 47.41% in 2025.
  • A 3-year view of Assets shows it stood at $303.8 million in 2023, then surged by 44.44% to $438.7 million in 2024, then increased by 2.26% to $448.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Assets are $448.7 million (Q4 2025), $459.8 million (Q3 2025), and $359.6 million (Q2 2025).